Loading
Every dated change on the records linked to Sezary syndrome, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Relapsed/refractory mycosis fungoides or Sézary syndrome after ≥1 systemic therapy
Mogamulizumab improved progression-free survival over vorinostat in previously treated mycosis fungoides and Sezary syndrome; approved in August 2018.